NCI/ADR-RES Cell Line
Model for the study of drug resistance in ovarian cancer
Contributors
| Inventor | Institute |
|---|---|
| Kenneth H. Cowan | National Cancer Institute |
| Cat. #: | 161022 |
|---|---|
| Cancer types: | Gynaecologic cancer |
| Research Fields: | Cancer |
| Organism: | Human |
| Tissue: | Ovary |
| Growth properties: | Adherent |
| Cancer Types In Detail: | Gynaecologic cancer;Ovarian |
| Primary citation: | Batist G, et al. J Biol Chem. 1986 Nov 25;261(33):15544-9. PMID: 3782078 |
| Product description: | The NCI/ADR-RES cell line is a multidrug-resistant human ovarian cancer cell line derived from the OVCAR-8 parental line. It is widely used in cancer research to investigate mechanisms of chemoresistance, particularly those involving the overexpression of the MDR1 gene, which encodes the drug efflux transporter P-glycoprotein. This cell line is part of the NCI-60 panel developed by the U.S. National Cancer Institute and serves as a valuable model for evaluating anticancer agents and studying strategies to overcome multidrug resistance. Notably, NCI/ADR-RES was previously misidentified as a derivative of the MCF-7 breast cancer cell line and referred to as MCF-7/ADR, a misclassification that was later corrected through molecular and genomic profiling. |
|---|---|
| CRISPR: | No |
| Production details: | The MCF-7/ADR cell line was first described in 1986 by Batist et al., who developed it by exposing the MCF-7 breast cancer cell line (mis-identified) to increasing concentrations of the chemotherapeutic drug adriamycin (doxorubicin). This process led to the selection of a stable, multidrug-resistant subline that overexpressed P-glycoprotein (MDR1/ABCB1), making it a widely used model for studying drug resistance in cancer. |
| Additional notes: | Spectral karyotyping of the 59 cell lines currently in the drug screen panel demonstrates that the Ovarian tumor cell line OVCAR-8 shares a large number of karyotypic abnormalities with the NCI/ADR-RES line. |
| Cellosaurus ID: | CVCL_1452 |
| Parental cell line: | OVCAR-8 |
| disease: | Cancer;Ovarian cancer;High Grade Serous Epithelial Ovarian cancer |
| Format: | Frozen |
|---|---|
| Storage conditions: | Liquid Nitrogen |
| Shipping conditions: | Dry Ice |
| Growth medium: | RPMI 1640 + 10% FBS + 50 U/mL Penicillin + 50 μg/mL Streptomycin + 1.84 μM Doxorubicin (to maintain resistance phenotype). |
| Temperature: | 37° C |
| Atmosphere: | 5% CO2 |
| References: |
Kunkel, et al. Cancer Res. 2024 Aug 1:84(15):2403-2416. PMID: 38861359 Gholami, et al. Cell Rep. 2013 Aug 15:4(3):609-20. PMID: 23933261 Ke, et al. Med Oncol. 2011 Dec:28 Suppl 1: S135-41. PMID: 21116879 Liscovitch and Ravid. Cancer Lett. 2007 Jan 8:245(1-2):350-2. PMID: 16504380 Adams, et al. J Transl Med. 2005 Mar 4:3(1):1. PMID: 15748285 D A Scudiero, et al. J Natl Cancer Inst. 1998 Jun 3:90(11):862. PMID: 9625176 O'Connor PM, et al. Cancer Res. 1997 Oct 1:57(19):4285-90. PMID: 9331090 Batist G, et al. J Biol Chem. 1986 Nov 25:261(33):15544-9. PMID: 3782078. |
|---|
Related Tools for Cell lines
| Cat. # | Tool Name | |||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 151447 | CMT 64 Cell Line |
Key Info
CMT 64 Cell Line
|
View Tool | |||||||||||||
| 151484 | 2fTGH Cell Line |
Key Info
2fTGH Cell Line
|
View Tool | |||||||||||||
| 151631 | C-Raf KI D486A Cell Line |
Key Info
C-Raf KI D486A Cell Line
|
View Tool | |||||||||||||
| 151655 | FLYA-13 Cell Line |
Key Info
FLYA-13 Cell Line
|
View Tool | |||||||||||||
| 151665 | MEF PKCe KO Cell Line |
Key Info
MEF PKCe KO Cell Line
|
View Tool | |||||||||||||
